AstraZeneca Opens Clinical Research Facility In China

Published September 2007

BEIJING, CHINA -

AstraZeneca has partnered with Peking University to open the Clinical Pharmacology Unit (CPU) on Sept. 4, 2007 in Beijing, China. Accommodating research on therapies for infections, diabetes, and cardiovascular diseases, the facility will accelerate progress from phase one drug development to the subsequent phases of clinical research. AstraZeneca is investing funds for facility upgrades to support clinical research and will provide personnel training, consulting, and system audits to Peking University Third Hospital. The Clinical Pharmacology Unit will enhance China’s clinical R&D operations and support local pharmacology organizations. 

Copyright 2008 Tradeline Inc.
All Rights Reserved
ISSN: 1096-4894